Roche wins US antitrust nod for USD 4.3 billion deal to buy Spark Therapeutics
The FTC approved the deal, which was originally announced in February, without requiring any asset sales to ensure that the planned merger complies with antitrust law, the agency said in a statement.
New Delhi: Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics, the Federal Trade Commission said on Monday, clearing the way for the Swiss drugmaker's push into treating rare diseases including haemophilia A.
Read Also: Roche Tecentriq cocktail shows progression-free survival in melanoma patient
The FTC approved the deal, which was originally announced in February, without requiring any asset sales to ensure that the planned merger complies with antitrust law, the agency said in a statement.
Read Also: Roche secures CE Mark for Accu-Chek SugarView app for diabetes management
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd